TRU-SENTIMENT ยท DeltaNeutral
MLTX Trading Analysis - 11/18/2026 02:19 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
MLTX (MoonLake Immunotherapeutics Class A Ordinary Share) at $11.01. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $17,245 vs put $0. RSI 42.4.
- Symbol
- MLTX
- Price
- $11.01
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- low
- Published
- 2026-11-18 14:19:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Call Volume: $17,245 (100.00%) Put Volume: $0 (0.00%) Total: $17,245
Methodology: Delta 40-60 only. Sentiment: Bullish. 169 call contracts vs 0 puts, 3 call trades. Pure directional conviction is call-heavy but on only $17.2K notional (filter ratio 0.9% of 346 options). This suggests minor bullish positioning, diverging from bearish technical alignment. Options flow is the only sentiment source; no X posts retrieved.
Key Statistics: MLTX
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-3.66 |
| Market cap | $935.33M |
| Shares outstanding | 85.1M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.06 |
| 52-week low | $9.46 |
| 52-week high | $23.29 |
| Historical volatility | 80.3% |
Ownership & trading
| Institutional ownership | 10.5% |
| Average daily volume | 1.7M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
Recent general-knowledge context for MLTX (MoonLake Immunotherapeutics, a clinical-stage biotech focused on inflammatory diseases):
- Company presented positive interim Phase 2 skin biopsy data for nanobody IL-17 inhibitor at a major dermatology conference, reinforcing pipeline optimism.
- Management outlined upcoming pivotal trial readout timeline, with a key catalyst expected in the coming quarters rather than next 25 days.
- No earnings release scheduled within the immediate 25-day window based on typical fiscal calendar; fiscal year end is 2025-12-01 per fundamentals.
- Low institutional ownership (10.51%) suggests limited street coverage and potential for volatile retail-driven moves on news.
- Headlines reflect long-term pipeline promise, but the embedded data shows near-term technical softness and tiny bullish options flow โ news context does not override the current data divergence.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing EPS is -3.66; company is unprofitable with no trailing PE (null) and no forward PE (null).
- Revenue growth, gross/operating/net margins, ROE, and free cash flow are all null โ not disclosed in dataset.
- Debt/equity, PEG ratio, and price/book are null; cannot assess leverage or relative valuation vs peers.
- Market cap is $935,325,930 with 85,107,000 shares out; 52-week range is $9.46 to $23.29 (current ~$11.13 near low third).
- Institutional holding is only 10.51%; beta is 0.06 (very low market correlation).
- Historical volatility is 80.32%; average volume 1,663,000; dividend yield 0.00%.
- Analyst consensus, target mean price, and number of opinions are null โ no street target context.
- Fundamentals (no earnings, low institutional base) diverge from the bullish options sentiment and show a speculative small-cap biotech with weak measurable fundamentals.
Current Market Position
Current price per indicators is $11.13 (2026-11-17 close). Minute bars show 2026-11-17 open $11.72 dropping to low $10.93 and close $11.13; 2026-11-18 intraday traded $11.65 down to $10.99 then $11.01 at 13:50. Recent daily action: peaked $13.90 on 2026-11-11, faded to $11.70 (11-16) and $11.13 (11-17). Intraday momentum is weak/sideways near $11.00โ$11.02 with volume spikes (19,123 at 13:45 11-18).
Technical Analysis
Technical Indicators
Price ($11.13) is below SMA5 ($12.40), SMA20 ($11.98), and SMA50 ($11.76) โ bearish alignment, no golden cross. RSI 42.42 shows weak momentum, not oversold. MACD histogram +0.02 is marginally bullish but negligible. Bollinger mid $11.98 / lower $10.54; price sits in lower band. 30d range $9.48โ$13.90: price is ~14% above low, ~20% below high.
True Sentiment Analysis (Delta 40-60 Options)
Call Volume: $17,245 (100.00%) Put Volume: $0 (0.00%) Total: $17,245
Methodology: Delta 40-60 only. Sentiment: Bullish. 169 call contracts vs 0 puts, 3 call trades. Pure directional conviction is call-heavy but on only $17.2K notional (filter ratio 0.9% of 346 options). This suggests minor bullish positioning, diverging from bearish technical alignment. Options flow is the only sentiment source; no X posts retrieved.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.